The bilirubin blood test market size has grown strongly in recent years. It will grow from $1.46 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rise in neonatal jaundice screening programs, increasing hospital-based liver function testing, growth in diagnostic awareness of liver disorders, adoption of serum bilirubin testing in routine clinical practice, expansion of pediatric and infant diagnostic services.
The bilirubin blood test market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing burden of chronic liver disease and hepatitis, rising demand for early liver health assessment, increasing utilization of bilirubin testing in primary care settings, higher testing rates in aging and at-risk patient populations, expansion of point-of-care and specialty liver diagnostics. Major trends in the forecast period include increasing use of bilirubin testing for liver function assessment, growing adoption of bilirubin tests in neonatal jaundice screening, rising testing demand in hematology and preliver disorder evaluation, expansion of bilirubin monitoring across hospital and clinical settings, focus on early detection and routine screening for liver health.
The increasing incidence of liver diseases is expected to drive the growth of the bilirubin blood test market in the coming years. Liver diseases encompass a variety of conditions that hinder normal liver function and may arise from causes such as infections, excessive alcohol intake, or metabolic disorders. The rise in liver disease cases is largely linked to growing obesity rates, high alcohol consumption, viral infections, and unhealthy lifestyle habits, all of which contribute to liver damage and dysfunction. Liver disease can markedly affect bilirubin levels in the body, and bilirubin blood tests are used to diagnose and monitor liver function, offering essential information about patient health while supporting healthcare professionals in the effective management and treatment of liver-related conditions. For instance, in April 2023, according to GOV.UK, a UK-based department for science, innovation, and technology, hospital admission rates for liver disease rose from 150.6 (148.2-152.9) to 155.2 (152.9-157.5) per 100,000 population between the financial years ending 2022 and 2023, highlighting a sustained upward trend in liver disease-related hospitalizations. Therefore, the growing incidence of liver diseases is driving the growth of the bilirubin blood test market.
Leading companies in the bilirubin blood test market are increasingly forming strategic partnerships to broaden their reach and improve their offerings. A strategic partnership involves a collaborative relationship between organizations that combines resources and expertise to achieve mutual goals. For example, in December 2023, Calmark Sweden AB, an Israel-based medical diagnostic biotechnology firm, entered into an exclusive distributor agreement with Techno Orbits in Saudi Arabia for its bilirubin test for newborns. Techno Orbits will manage the distribution and sales of Calmark’s product, utilizing its established network and connections, including with the Ministry of Health. This partnership aims to facilitate the introduction of Calmark’s bilirubin test into the Saudi market, with regulatory registration expected to take between 3 to 6 months.
In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based medical technology provider, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed sum. This acquisition is designed to bolster Mindray’s competitive position in the in vitro diagnostic (IVD) sector by leveraging DiaSys’s established supply chains and expertise in clinical chemistry. The acquisition is expected to enhance Mindray’s capabilities in serving medium- to large-volume customers and improve service delivery. DiaSys Diagnostic Systems GmbH, based in Germany, specializes in diagnostic systems, including bilirubin blood tests for liver diseases.
Major companies operating in the bilirubin blood test market are Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann‑La Roche Ltd, Siemens Healthineers, Danaher Corporation, Sysmex Corporation, Bio‑Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, Mindray Medical International Limited, Randox Laboratories Ltd, bioMérieux SA, DiaSorin S.p.A, Horiba Ltd, ELITech Group SAS, Erba Mannheim, Hitachi High‑Technologies, DIRUI Industrial Co Ltd, Agappe Diagnostics, Awareness Technology Inc, Sekisui Diagnostics.
North America was the largest region in the bilirubin blood test market in 2025. The regions covered in the bilirubin blood test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bilirubin blood test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are affecting the bilirubin blood test market by increasing the costs of diagnostic analyzers, reagent kits, assay consumables, and laboratory instrumentation components that depend on cross-border supply chains, leading to higher procurement and testing costs. The impact is most evident across hospitals and clinical laboratories, especially in regions such as Asia-Pacific and Europe where reagent imports and analyzer components are tariff sensitive. Pediatric, infant, and adult testing segments are experiencing cost pressures and slower equipment upgrade cycles due to tariff-driven price pass-throughs. At the same time, tariffs are encouraging localized reagent manufacturing, regional analyzer assembly, and domestic supply chain development, which may strengthen long-term production resilience and market stability.
The bilirubin blood test market research report is one of a series of new reports that provides bilirubin blood test market statistics, including bilirubin blood test industry global market size, regional shares, competitors with a bilirubin blood test market share, detailed bilirubin blood test market segments, market trends and opportunities, and any further data you may need to thrive in the bilirubin blood test industry. This bilirubin blood test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bilirubin blood test is a diagnostic procedure used to measure bilirubin levels in the blood. This test is important for evaluating liver function and diagnosing conditions such as jaundice and liver disease. It is crucial for assessing bilirubin metabolism and identifying liver health issues.
The main types of bilirubin blood tests includes the total serum bilirubin test, the indirect or unconjugated bilirubin test, and the direct or conjugated bilirubin test. The total serum bilirubin test measures the combined amount of unconjugated (indirect) and conjugated (direct) bilirubin in the blood. This test is essential for assessing overall liver health and diagnosing various liver-related conditions. The test is applicable to adults, pediatrics, and infants, and it is used in hospitals, clinics, and other healthcare settings.
The bilirubin blood test market consists of sales of products such as diagnostic devices for measuring bilirubin levels, including test kits, blood analyzers, and automated testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The bilirubin blood test market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing burden of chronic liver disease and hepatitis, rising demand for early liver health assessment, increasing utilization of bilirubin testing in primary care settings, higher testing rates in aging and at-risk patient populations, expansion of point-of-care and specialty liver diagnostics. Major trends in the forecast period include increasing use of bilirubin testing for liver function assessment, growing adoption of bilirubin tests in neonatal jaundice screening, rising testing demand in hematology and preliver disorder evaluation, expansion of bilirubin monitoring across hospital and clinical settings, focus on early detection and routine screening for liver health.
The increasing incidence of liver diseases is expected to drive the growth of the bilirubin blood test market in the coming years. Liver diseases encompass a variety of conditions that hinder normal liver function and may arise from causes such as infections, excessive alcohol intake, or metabolic disorders. The rise in liver disease cases is largely linked to growing obesity rates, high alcohol consumption, viral infections, and unhealthy lifestyle habits, all of which contribute to liver damage and dysfunction. Liver disease can markedly affect bilirubin levels in the body, and bilirubin blood tests are used to diagnose and monitor liver function, offering essential information about patient health while supporting healthcare professionals in the effective management and treatment of liver-related conditions. For instance, in April 2023, according to GOV.UK, a UK-based department for science, innovation, and technology, hospital admission rates for liver disease rose from 150.6 (148.2-152.9) to 155.2 (152.9-157.5) per 100,000 population between the financial years ending 2022 and 2023, highlighting a sustained upward trend in liver disease-related hospitalizations. Therefore, the growing incidence of liver diseases is driving the growth of the bilirubin blood test market.
Leading companies in the bilirubin blood test market are increasingly forming strategic partnerships to broaden their reach and improve their offerings. A strategic partnership involves a collaborative relationship between organizations that combines resources and expertise to achieve mutual goals. For example, in December 2023, Calmark Sweden AB, an Israel-based medical diagnostic biotechnology firm, entered into an exclusive distributor agreement with Techno Orbits in Saudi Arabia for its bilirubin test for newborns. Techno Orbits will manage the distribution and sales of Calmark’s product, utilizing its established network and connections, including with the Ministry of Health. This partnership aims to facilitate the introduction of Calmark’s bilirubin test into the Saudi market, with regulatory registration expected to take between 3 to 6 months.
In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based medical technology provider, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed sum. This acquisition is designed to bolster Mindray’s competitive position in the in vitro diagnostic (IVD) sector by leveraging DiaSys’s established supply chains and expertise in clinical chemistry. The acquisition is expected to enhance Mindray’s capabilities in serving medium- to large-volume customers and improve service delivery. DiaSys Diagnostic Systems GmbH, based in Germany, specializes in diagnostic systems, including bilirubin blood tests for liver diseases.
Major companies operating in the bilirubin blood test market are Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann‑La Roche Ltd, Siemens Healthineers, Danaher Corporation, Sysmex Corporation, Bio‑Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, Mindray Medical International Limited, Randox Laboratories Ltd, bioMérieux SA, DiaSorin S.p.A, Horiba Ltd, ELITech Group SAS, Erba Mannheim, Hitachi High‑Technologies, DIRUI Industrial Co Ltd, Agappe Diagnostics, Awareness Technology Inc, Sekisui Diagnostics.
North America was the largest region in the bilirubin blood test market in 2025. The regions covered in the bilirubin blood test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bilirubin blood test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are affecting the bilirubin blood test market by increasing the costs of diagnostic analyzers, reagent kits, assay consumables, and laboratory instrumentation components that depend on cross-border supply chains, leading to higher procurement and testing costs. The impact is most evident across hospitals and clinical laboratories, especially in regions such as Asia-Pacific and Europe where reagent imports and analyzer components are tariff sensitive. Pediatric, infant, and adult testing segments are experiencing cost pressures and slower equipment upgrade cycles due to tariff-driven price pass-throughs. At the same time, tariffs are encouraging localized reagent manufacturing, regional analyzer assembly, and domestic supply chain development, which may strengthen long-term production resilience and market stability.
The bilirubin blood test market research report is one of a series of new reports that provides bilirubin blood test market statistics, including bilirubin blood test industry global market size, regional shares, competitors with a bilirubin blood test market share, detailed bilirubin blood test market segments, market trends and opportunities, and any further data you may need to thrive in the bilirubin blood test industry. This bilirubin blood test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bilirubin blood test is a diagnostic procedure used to measure bilirubin levels in the blood. This test is important for evaluating liver function and diagnosing conditions such as jaundice and liver disease. It is crucial for assessing bilirubin metabolism and identifying liver health issues.
The main types of bilirubin blood tests includes the total serum bilirubin test, the indirect or unconjugated bilirubin test, and the direct or conjugated bilirubin test. The total serum bilirubin test measures the combined amount of unconjugated (indirect) and conjugated (direct) bilirubin in the blood. This test is essential for assessing overall liver health and diagnosing various liver-related conditions. The test is applicable to adults, pediatrics, and infants, and it is used in hospitals, clinics, and other healthcare settings.
The bilirubin blood test market consists of sales of products such as diagnostic devices for measuring bilirubin levels, including test kits, blood analyzers, and automated testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Bilirubin Blood Test Market Characteristics
3. Bilirubin Blood Test Market Supply Chain Analysis
4. Global Bilirubin Blood Test Market Trends and Strategies
5. Bilirubin Blood Test Market Analysis of End Use Industries
7. Global Bilirubin Blood Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Bilirubin Blood Test Total Addressable Market (TAM) Analysis for the Market
9. Bilirubin Blood Test Market Segmentation
10. Bilirubin Blood Test Market Regional and Country Analysis
11. Asia-Pacific Bilirubin Blood Test Market
12. China Bilirubin Blood Test Market
13. India Bilirubin Blood Test Market
14. Japan Bilirubin Blood Test Market
15. Australia Bilirubin Blood Test Market
16. Indonesia Bilirubin Blood Test Market
17. South Korea Bilirubin Blood Test Market
18. Taiwan Bilirubin Blood Test Market
19. South East Asia Bilirubin Blood Test Market
20. Western Europe Bilirubin Blood Test Market
21. UK Bilirubin Blood Test Market
22. Germany Bilirubin Blood Test Market
23. France Bilirubin Blood Test Market
24. Italy Bilirubin Blood Test Market
25. Spain Bilirubin Blood Test Market
26. Eastern Europe Bilirubin Blood Test Market
27. Russia Bilirubin Blood Test Market
28. North America Bilirubin Blood Test Market
29. USA Bilirubin Blood Test Market
30. Canada Bilirubin Blood Test Market
31. South America Bilirubin Blood Test Market
32. Brazil Bilirubin Blood Test Market
33. Middle East Bilirubin Blood Test Market
34. Africa Bilirubin Blood Test Market
36. Bilirubin Blood Test Market Competitive Landscape and Company Profiles
37. Bilirubin Blood Test Market Other Major and Innovative Companies
40. Bilirubin Blood Test Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Bilirubin Blood Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses bilirubin blood test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bilirubin blood test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bilirubin blood test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Total Serum Bilirubin Test; Indirect Or Unconjugated Bilirubin Test; Direct Or Conjugated Bilirubin Test2) By Age Group: Adults; Pediatrics; Infants
3) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Total Serum Bilirubin Test: Routine Screening; Liver Function Assessment; Newborn Jaundice Detection2) By Indirect Or Unconjugated Bilirubin Test: Hemolytic Anemia Diagnosis; Gilbert's Syndrome Detection; Monitoring For Preliver Conditions
3) By Direct Or Conjugated Bilirubin Test: Bile Duct Obstruction Diagnosis; Hepatitis And Liver Disease Monitoring; Post-Liver Condition Assessment
Companies Mentioned: Abbott Laboratories; Thermo Fisher Scientific; F. Hoffmann‑La Roche Ltd; Siemens Healthineers; Danaher Corporation; Sysmex Corporation; Bio‑Rad Laboratories Inc; Ortho Clinical Diagnostics Inc; Mindray Medical International Limited; Randox Laboratories Ltd; bioMérieux SA; DiaSorin S.p.A; Horiba Ltd; ELITech Group SAS; Erba Mannheim; Hitachi High‑Technologies; DIRUI Industrial Co Ltd; Agappe Diagnostics; Awareness Technology Inc; Sekisui Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Bilirubin Blood Test market report include:- Abbott Laboratories
- Thermo Fisher Scientific
- F. Hoffmann‑La Roche Ltd
- Siemens Healthineers
- Danaher Corporation
- Sysmex Corporation
- Bio‑Rad Laboratories Inc
- Ortho Clinical Diagnostics Inc
- Mindray Medical International Limited
- Randox Laboratories Ltd
- bioMérieux SA
- DiaSorin S.p.A
- Horiba Ltd
- ELITech Group SAS
- Erba Mannheim
- Hitachi High‑Technologies
- DIRUI Industrial Co Ltd
- Agappe Diagnostics
- Awareness Technology Inc
- Sekisui Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.57 Billion |
| Forecasted Market Value ( USD | $ 2.08 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
